UA74388C2 - Фармацевтичні композиції тизоксаніду і нітазоксаніду - Google Patents

Фармацевтичні композиції тизоксаніду і нітазоксаніду

Info

Publication number
UA74388C2
UA74388C2 UA2003042974A UA200342974A UA74388C2 UA 74388 C2 UA74388 C2 UA 74388C2 UA 2003042974 A UA2003042974 A UA 2003042974A UA 200342974 A UA200342974 A UA 200342974A UA 74388 C2 UA74388 C2 UA 74388C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical compositions
tysoxanide
nitasoxanide
compound
active ingredient
Prior art date
Application number
UA2003042974A
Other languages
English (en)
Russian (ru)
Inventor
Жан-Франсуа Россігнол
Original Assignee
Ромарк Лабораторіз, Ел. Сі.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA74388(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/852,447 external-priority patent/US5968961A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Ромарк Лабораторіз, Ел. Сі. filed Critical Ромарк Лабораторіз, Ел. Сі.
Publication of UA74388C2 publication Critical patent/UA74388C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Фармацевтичні композиції, які містять як активний агент щонайменше одну сполуку, вибрану з групи, що складається з сполуки формули (І) та/або сполуки формули (II). Причому активний агент присутній переважно у вигляді частинок, що мають розмір менше 200 мкм, та фармацевтичні композиції стабілізовані щонайменше однією фармацевтично прийнятною кислотою. Використовують при лікуванні інфекційних захворювань. (І) (ІІ).
UA2003042974A 1997-05-07 2003-04-04 Фармацевтичні композиції тизоксаніду і нітазоксаніду UA74388C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
UA74388C2 true UA74388C2 (uk) 2005-12-15

Family

ID=27420362

Family Applications (2)

Application Number Title Priority Date Filing Date
UA99126626A UA57079C2 (uk) 1997-05-07 1998-06-05 Фармацевтична композиція тизоксаніду і нітазоксаніду (варіанти)
UA2003042974A UA74388C2 (uk) 1997-05-07 2003-04-04 Фармацевтичні композиції тизоксаніду і нітазоксаніду

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA99126626A UA57079C2 (uk) 1997-05-07 1998-06-05 Фармацевтична композиція тизоксаніду і нітазоксаніду (варіанти)

Country Status (34)

Country Link
EP (2) EP1005342B1 (uk)
JP (1) JP3739802B2 (uk)
KR (2) KR100576646B1 (uk)
CN (2) CN100515420C (uk)
AP (1) AP1103A (uk)
AR (1) AR057242A2 (uk)
AT (2) ATE281166T1 (uk)
AU (1) AU740022B2 (uk)
BG (2) BG109365A (uk)
BR (1) BR9808722A (uk)
CA (2) CA2288003C (uk)
CZ (2) CZ298269B6 (uk)
DE (2) DE69827417T2 (uk)
DK (2) DK1222921T3 (uk)
EA (2) EA002908B1 (uk)
EE (1) EE04870B1 (uk)
ES (2) ES2232687T3 (uk)
GE (1) GEP20032970B (uk)
HU (1) HU229641B1 (uk)
IL (2) IL132516A (uk)
IS (1) IS2087B (uk)
LV (1) LV12492B (uk)
ME (1) ME00530B (uk)
NO (2) NO313983B1 (uk)
NZ (2) NZ513881A (uk)
OA (1) OA11169A (uk)
PL (1) PL193275B1 (uk)
PT (2) PT1005342E (uk)
RO (1) RO120605B1 (uk)
SI (1) SI20149B (uk)
SK (2) SK283946B6 (uk)
TR (1) TR199902733T2 (uk)
UA (2) UA57079C2 (uk)
WO (1) WO1998050035A1 (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
BRPI1007945C8 (pt) * 2009-02-13 2021-05-25 Romark Laboratories Lc formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
EP3078377A3 (en) 2009-05-12 2017-04-05 Romark Laboratories, L.C. Nitazoxanide and tizoxanide as anti-viral agents
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
MX340846B (es) 2012-01-27 2016-07-28 Rhein Siegfried Sa De Cv Composición de nitazoxanida mejorada y proceso para prepararla.
CN107105660A (zh) * 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
WO2019148294A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives

Also Published As

Publication number Publication date
HUP0003330A2 (hu) 2001-05-28
IL155799A0 (en) 2003-12-23
CN1552322A (zh) 2004-12-08
NO995406L (no) 2000-01-04
JP3739802B2 (ja) 2006-01-25
CN1158074C (zh) 2004-07-21
KR100576646B1 (ko) 2006-05-08
AU740022B2 (en) 2001-10-25
EP1222921B1 (en) 2004-11-03
EA199901012A1 (ru) 2000-08-28
NO313983B1 (no) 2003-01-13
DK1222921T3 (da) 2005-03-07
SK151199A3 (en) 2000-07-11
SK283946B6 (sk) 2004-05-04
EP1005342B1 (en) 2002-12-04
SI20149A (sl) 2000-08-31
CZ298269B6 (cs) 2007-08-08
NO20021832L (no) 2000-01-04
NO20021832D0 (no) 2002-04-18
NZ513881A (en) 2002-10-25
DK1005342T3 (da) 2003-03-24
CZ298270B6 (cs) 2007-08-08
PT1005342E (pt) 2003-02-28
IS2087B (is) 2006-03-15
AU7289598A (en) 1998-11-27
EP1005342A4 (en) 2001-02-07
ES2150404T1 (es) 2000-12-01
EA002920B1 (ru) 2002-10-31
OA11169A (en) 2003-04-25
HU229641B1 (en) 2014-03-28
EE9900578A (et) 2000-08-15
GEP20032970B (en) 2003-05-27
BG109365A (en) 2006-08-31
AP1103A (en) 2002-09-04
CA2418634A1 (en) 1998-11-12
ME00530B (me) 2011-10-10
DE69827417D1 (de) 2004-12-09
IS5223A (is) 1999-10-19
KR20010020322A (ko) 2001-03-15
LV12492B (en) 2001-01-20
EP1005342A1 (en) 2000-06-07
NZ500149A (en) 2001-11-30
SI20149B (en) 2001-08-31
KR20040004544A (ko) 2004-01-13
IL132516A (en) 2003-12-10
PL336805A1 (en) 2000-07-17
IL132516A0 (en) 2001-03-19
BG64973B1 (bg) 2006-11-30
NO995406D0 (no) 1999-11-04
EP1222921A1 (en) 2002-07-17
EA200100956A1 (ru) 2002-02-28
NO335781B1 (no) 2015-02-16
AR057242A2 (es) 2007-11-21
IL155799A (en) 2004-08-31
CZ391199A3 (cs) 2000-07-12
AP9901675A0 (en) 1999-12-31
CA2418634C (en) 2004-10-26
LV12492A (en) 2000-06-20
PL193275B1 (pl) 2007-01-31
ATE281166T1 (de) 2004-11-15
EA002908B1 (ru) 2002-10-31
HUP0003330A3 (en) 2002-10-28
SK283947B6 (sk) 2004-05-04
CN1255060A (zh) 2000-05-31
DE69827417T2 (de) 2005-10-27
DE69809928T2 (de) 2003-04-24
WO1998050035A1 (en) 1998-11-12
BR9808722A (pt) 2000-07-11
HK1025907A1 (en) 2000-12-01
ATE228839T1 (de) 2002-12-15
ES2232687T3 (es) 2005-06-01
KR100426657B1 (ko) 2004-04-13
UA57079C2 (uk) 2003-06-16
BG103958A (en) 2000-07-31
CA2288003A1 (en) 1998-11-12
EE04870B1 (et) 2007-08-15
CA2288003C (en) 2003-10-21
TR199902733T2 (xx) 2000-03-21
PT1222921E (pt) 2005-02-28
CN100515420C (zh) 2009-07-22
RO120605B1 (ro) 2006-05-30
DE69809928D1 (de) 2003-01-16
JP2001503067A (ja) 2001-03-06
ES2150404T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
CA2203033A1 (en) Compounds and compositions for delivering active agents
IT1304152B1 (it) Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
HUT64065A (en) Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient
MY115339A (en) Compositions containing micronized nebivolol
GEP20002211B (en) Taxoids, Preparation Thereof, Pharmaceutical Compositions Containing Same
IL114641A (en) Pharmaceutical compositions containing dispersible fluoxetine
HUT59106A (en) Process for producing 3-amidopyrazoles and pharmaceutical compositions comprising such compounds as active ingredient
CA2338358A1 (en) Compounds and compositions for delivering active agents
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
CA2289717A1 (en) Novel therapy for constipation
HU9301550D0 (en) New hydroxamine acid and n-hydroxy-carbamide derivatives and their applications
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
AU4245289A (en) Psyllium-containing products
BG103958A (en) Pharmaceutical compositions of thioxanide and nitazoxanide
AU3777197A (en) Cyclosporin formulation
HUT61024A (en) Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
DE3474024D1 (en) Contraceptive compositions based on esters of levo-norgestrel
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
EP0820770A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und ein Antioxidans enthält
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
HRP940315B1 (en) Process for the preparation of pharmaceutical compositions containinbg active ingredient
EP0820771A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält